pharma news today glp-1 health obesity drugs october 2025 Outlook for obesity in 2025: more GLP-1 Pharma Marketing Strategy for

Raz I., Hanefeld M., Xu L., et al., Efficacy and Safety of the Dipeptidyl Peptidase4 Inhibitor Sitagliptin as Monotherapy in Patients With Type 2 Diabetes Mellitus, Diabetologia 49 (2006): 25642571

References Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ

It's akin to bariatric surgery, Sheer said of the amount of weight loss these drugs unlock

Considerations regarding travel time if the service is to be delivered on a PCN wide basis needs careful planning also

Who Is Peak Wellness Not For

A local presence in Asia combined with global resources and innovation capabilities enables delivery of not just containment and delivery solutions, but also the strategic support needed to navigate complex regulatory landscapes and scale globally